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Abstract
Background: The body of disease mutations with known phenotypic relevance continues to increase and is
expected to do so even faster with the advent of new experimental techniques such as whole-genome
sequencing coupled with disease association studies. However, genomic association studies are limited by the
molecular complexity of the phenotype being studied and the population size needed to have adequate statistical
power. One way to circumvent this problem, which is critical for the study of rare diseases, is to study the
molecular patterns emerging from functional studies of existing disease mutations. Current gene-centric analyses to
study mutations in coding regions are limited by their inability to account for the functional modularity of the
protein. Previous studies of the functional patterns of known human disease mutations have shown a significant
tendency to cluster at protein domain positions, namely position-based domain hotspots of disease mutations.
However, the limited number of known disease mutations remains the main factor hindering the advancement of
mutation studies at a functional level. In this paper, we address this problem by incorporating mutations known to
be disruptive of phenotypes in other species. Focusing on two evolutionarily distant organisms, human and yeast,
we describe the first inter-species analysis of mutations of phenotypic relevance at the protein domain level.
Results: The results of this analysis reveal that phenotypic mutations from yeast cluster at specific positions on
protein domains, a characteristic previously revealed to be displayed by human disease mutations. We found over
one hundred domain hotspots in yeast with approximately 50% in the exact same domain position as known
human disease mutations.
Conclusions: We describe an analysis using protein domains as a framework for transferring functional information
by studying domain hotspots in human and yeast and relating phenotypic changes in yeast to diseases in human.
This first-of-a-kind study of phenotypically relevant yeast mutations in relation to human disease mutations
demonstrates the utility of a multi-species analysis for advancing the understanding of the relationship between
genetic mutations and phenotypic changes at the organismal level.
Background
The study of human genomic variations, in particular
those in protein coding regions, can lead to new hypoth-
eses about the molecular mechanisms of human diseases
and might provide critical knowledge about individual
response to therapy [1,2]. The advent of large-scale
experimental techniques is providing new phenotypic
associations for genomic variations [3-5]. However,
genomic association studies are limited by the molecular
complexity of the phenotype being studied and the
cohort size needed to have adequate statistical power.
One way to circumvent this problem, which is critical in
the study of rare diseases, is to investigate the molecular
patterns emerging from functional studies of existing
* Correspondence: mkann@umbc.edu
1Department of Biological Sciences, University of Maryland, Baltimore
County, Baltimore, MD, USA
Full list of author information is available at the end of the article
Peterson et al. BMC Genomics 2013, 14(Suppl 3):S5
http://www.biomedcentral.com/1471-2164/14/S3/S5
© 2013 Peterson et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
disease mutations. In current large association studies,
such as GWAS or upcoming whole-exome and whole-
genome sequencing, this is accomplished by aggregating
mutations that disrupt the same gene [6,7], pathway [8],
or network [9]. In many cases, these molecular varia-
tions associated with human diseases have patterns that
are similar to those producing a phenotypic change in
other species. For example, the comparison between
close species has made significant contributions to the
biomedical field, such as the use of mice [10] and rats
[11] for genetics and drug discovery. In addition, studies
across species with longer evolutionary distances to
human have many advantages and could bring new per-
spectives into the study of molecular mechanisms of
human phenotypic variations. For instance, the func-
tional analysis of variations in yeast, an organism that
can be easily genetically manipulated, has shed light on
variations in their human gene orthologs, as shown in
McGary et al. [12]. The authors demonstrated the
potential of a systematic study of phenotypes produced
by variations in human and their orthologs in yeast or
other distantly related species, providing novel hypoth-
eses about human diseases, which have already resulted
in valuable leads for drug discovery.
The vast majority of studies related to human disease
mutations are performed by comparison of whole proteins,
which here will be denoted by the genes that encode them.
However, these whole-protein approaches are of limited
applicability to the study of disease mutations due to the
fact that they mostly fail to account for protein modularity.
Most proteins contain multiple domains that can be
recombined in different arrangements to create proteins
with different functions [13-15]. As a consequence, not all
protein regions have the same function or produce similar
phenotypic changes if disrupted. Thus, the specific loca-
tion of a particular mutation within the protein could be
crucial to understanding the mutation’s functional effect.
The relevance of studying protein domains in the context
of disease was also discussed by Zhong et al. [16] in their
study of protein interactions and their relation to diseases.
The authors showed that mutations resulting in complete
loss of the protein product (removal of a node in the net-
work) could be different from those disrupting only a pro-
tein region or domain (edgetic perturbations).
Furthermore, Zhong et al. conclude that these edgetic per-
turbations can cause clinically distinct phenotypes when
disrupting different protein domain regions of the same
protein. Thus, a domain-centric study of disease mutations
has the potential to differentiate among genomic varia-
tions by accounting for protein modularity that would
have otherwise been grouped together by whole-protein
studies.
To capture the disruption of domains by genetic muta-
tions, we have previously created a database to visualize
the aggregation patterns of disease mutations at the
protein and domain levels for human genomics data
(Domain Mapping of Disease Mutations database
(DMDM), freely available at http://bioinf.umbc.edu/
dmdm/) [17]. More recently, we have developed a sta-
tistical approach, the domain significance score (or
DS-Score), for finding significantly mutated positions for
individual protein domains [18]. We demonstrated that
significant DS-Scores indicate that a mutation at a speci-
fic position is highly likely to be a contributor to disease
in any protein containing the domain in which the muta-
tions are located. In particular, we have shown that Men-
delian disease mutations form clusters at protein domain
sites [18]. In addition, results from Yue et al. [19], Nehrt
et al. [20], and Peterson et al. [18] have further shown
that inherited and somatic cancer mutations cluster at
specific sites at the protein domain level. Thus, these stu-
dies show how the domain analysis enables the discovery
of domain hotspots of mutations with phenotypic rele-
vance by aggregating mutations that share the same
domain location but are localized in different genes.
However, the discovery of these highly deleterious
domain sites by aggregation of mutational data with
known phenotypic effect is limited by the availability of
such mutational data. As a result, the DS-Score method
based on human data has low coverage when analyzing
mutations from large-scale sequencing studies. To
address this issue, more annotated disease mutation data
will need to be incorporated into the analysis, preferably
from other species in which the phenotypic effect of
putative deleterious mutations could be experimentally
tested.
In this paper, we describe the first inter-species analysis
of mutations of phenotypic relevance at the protein
domain level for human and yeast genomes. We perform
the comparison between these species by mapping human
and yeast mutations into the corresponding domain sites.
Protein domains, such as those defined by CDD [21] and
Pfam [22], are protein sequence regions that are highly
conserved across distantly related species. For instance,
when comparing yeast and human domains, we estimate
that 87% of all the protein domains found in yeast are also
found in human while, using the Homologene database to
compare genes, only 20% of the yeast genes have a human
ortholog [23]. Similarly, 58% of the human domains are
shared with yeast while only 5% of the human genes have
yeast orthologs. Since yeast and human analyses show a
significant number of common domains, the protein
domain framework facilitates the comparison of a signifi-
cant number of mutations producing phenotypic changes
in both species. Using a domain-centric approach, we
show that phenotypically relevant mutations in yeast form
hotspots at the protein domain level, and that a significant
number of these hotspots map to known human disease
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mutations. Furthermore, our results show that the feature-
based DS-Score, a modification of our statistical method
that explicitly incorporates annotation from the protein
domain models, was most successful at capturing func-
tional commonalities between human and yeast mutations
affecting these organisms’ phenotypes.
In summary, the work described in this paper demon-
strates that domain-centric, inter-species mutation ana-
lyses lead to the identification of new domain sites of
relevance to human diseases even when performed
among species separated by long evolutionary distances.
The patterns of evolutionarily conserved and functional
mutations associated with phenotypic changes emerging
from this study represent a step towards a new para-




A human protein database containing 54,372 proteins was
created with 33,963 proteins from RefSeq [24] and 20,409
proteins from Swiss-Prot [25] downloaded via NCBI’s
E-utilities [23]. Since the RefSeq and Swiss-Prot databases
contain many redundant protein entries, we selected only
one representative protein for each unique Entrez gene
ID, either the longest Swiss-Prot protein, or the longest
RefSeq protein if no Swiss-Prot protein was listed for the
gene ID. A database of 6,717 verified and hypothetical
open reading frame yeast reference proteins was down-
loaded from the Saccharomyces Genome Database (SGD)
[26] on September 28th, 2012 (http://downloads.yeastgen-
ome.org/sequence/S288C_reference/orf_protein/). The
Homologene database [23] was downloaded from NCBI’s
FTP site on September 12th, 2011. A protein domain set
was obtained from the Conserved Domain Database (CDD
version 2.25) [21], which includes domains from CDD and
the SMART [27], COG [28], and Pfam [22] databases,
with a total of 23,632 protein domains, 10,925 of which
map to at least one human protein, and 7,369 map to at
least one yeast protein. Functional feature information was
collected for CDD domains from the “cddannot.dat” file
located in the CDD FTP directory (ftp://ftp.ncbi.nih.gov/
pub/mmdb/cdd), totaling 1,727 unique functional features.
The non-overlapping set of human, non-synonymous dis-
ease mutations was created from the OMIM [29] and
Swiss-Prot variant databases obtained from E-utilities and
UniProt’s FTP directory (http://www.uniprot.org/docs/
humsavar) respectively. The resulting human mutation
dataset consists of 32,653 mutations related to human dis-
eases. The set of phenotypic yeast mutations was down-
loaded from SGD (the phenotype_data.tab database
obtained from http://www.yeastgenome.org/download-
data/curation/) and was filtered to exclude records without
allelic information and records listing the phenotypic
change as “normal,” as these records refer to mutations
with no phenotypic change. Finally, the yeast mutation
database was manually curated to extract single point
mutations and to ensure that each mutation record
referred to a single point mutation. Mutation records refer-
ring to multiple mutations for a single phenotype were
separated into multiple records. The final yeast mutational
database is comprised of 1,490 unique mutations associated
with phenotypic changes and is available upon request.
Mapping mutations to protein domains
Hidden Markov models for protein domains from
SMART, COG, CDD, and Pfam were built using multiple
sequence alignments from CDD with the hmmerbuild
tool (HMMer version 2.3.2) [30]. HMMer’s hmmpfam
tool was then used with the global option to search for
complete domains in human proteins from the RefSeq
and Swiss-Prot databases. Protein mutations were distrib-
uted to protein domain positions by using HMMer’s
alignment output for all domains aligning to the protein
with an E-Value ≤ 0.001 and by assigning mutations on
gap regions of the domain model to the last position
before the gap. Each mutation was mapped only to the
representative protein for each unique gene in the data-
set. The methods for mapping domains to human pro-
teins and disease mutations to their domain positions
were previously described for our DMDM tool [17].
After distributing each mutation to all domains that map
to the protein position in which the mutation was
located, 4,283 human protein domains contained at least
one disease mutation and 1,687 yeast protein domains
contained at least one phenotypic yeast mutation.
Determining the level of conservation at each domain
position
For each column j in a protein domain multiple sequence
alignment, we used the AL2CO [31] method to deter-




p(ai,j) In (p(ai,j)), (1)
where p(ai,j) is the frequency of amino acid ai at position
j. We then estimated a threshold for identifying highly
conserved positions by adding one standard deviation to
the average of all AL2CO scores on all domain positions.
As a result, a threshold of entropy less than or equal to
0.533 was used to determine conservation. The average
entropy of each domain model was determined by esti-
mating the mean of the entropy scores for all positions in
the domain model.
Estimating domain significance scores (DS-Scores)
We used a method previously developed by our group [18]
to estimate the position-based and feature-based DS-Score
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for each position in the domain. Let n be the total number
of mutations in the domain and let L be the number of
possible positions in the domain. The random sample, X1,
... , XL consists of the numbers of mutations aggregated to
the domain level from a single organism (Figure 1A) or
from any number of organisms (Figure 1B) and let X(1) be
the smallest of these Xi , and X(2) be the next order of
magnitude, ... , and X(L) is the largest Xi. We used the
probability mass function, P(X = x), to test whether the n
mutations are randomly distributed into L positions.
Finally, we defined our position-based DS-Score by the
negative logarithm transformation of the binomial prob-
ability of observing a cluster of mutations of a particular
size, given the total available positions in a domain and
the total number of mutations observed. For consistency,
when the number of mutations is equal in m positions, we
assigned the same score to all m positions. Where k is the
kth order of the number of mutations at domain positions,
we define the DS-Score as




max (x) ≥ k and max (x) = x(L)
))

















We defined domain hotspots using three levels of sig-
nificance from the Fisher’s scale of evidence for inter-
preting p-values as described by Yue et al. [32], namely
p-values less than or equal to 0.025, 0.05, and 0.10.
Using these three levels of significance, we derived three
Figure 1 Aggregating mutations using protein domains to form domain hotspots. (A) Mutations from multiple proteins in a single
organism sharing a common protein domain mapped to the domain level. These mutations have different phenotypes but can be shown to
form a large cluster at a single position in the domain, indicating similarity. (B) Mutations from multiple organisms mapped to a protein domain.
These mutations form a large cluster of mutations at the domain level despite having originated from different species. (C) A domain hotspot is
formed using mutations from only organism 1, but mutations aligning to the same domain position from organism 2 do not have enough
mutations to form a domain hotspot. However, some association can still be drawn due to the existence of a domain hotspot in organism 1
aligning to a mutation in organism 2.
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DS-Score thresholds of greater than or equal to 1.6, 1.3,
or 1.0 corresponding to p-values less than or equal to
0.025, 0.05, and 0.10 respectively. In addition to posi-
tion-based DS-Scores, which are based solely on the
mutations found at a specific domain position, feature-
based DS-Scores were created by distributing the largest
position-based DS-Score for each functional feature to
all other positions with the same functional feature
annotation (see example in Figure 2). We define these
functional feature sites as domain positions that have
been manually annotated by CDD as having a known
functional role (e.g. a DNA binding site or a flexible
hinge region) [33]. Perl and R (http://www.r-project.org)
were used to determine and distribute the DS-Scores for
each domain position.
Mutations and protein domain redundancy
Due to large domain superfamily hierarchies and duplicate
domains from different sources, a single protein mutation
can be mapped to many redundant domains. As a conse-
quence, multiple domain hotspots can be identified on dif-
ferent domains that have originated from the same cluster
of mutations. On one hand, to ensure that the DS-Scores
and domain hotspots are estimated and identified for all
protein domain models, all mutations in our analysis were
distributed to all domains that map to the mutated protein
position. The results of our analysis for each individual
domain model, even for those domains from superfamily
hierarchies and disparate sources for which we expect
high redundancy, are available upon request. On the other
hand, to prevent overestimating the number of hotspots
shared between yeast and human, we designed a proce-
dure for the non-redundification of domain hotspots. As a
result, the numbers reported for all domain hotspots and
multi-species domain hotspots originated from a unique
set of mutation clusters. We excluded hotspots that origi-
nated from identical sets of mutations using the following
method to select a unique representative domain for clus-
ter of mutations. The representative domain is only used
for visualization and internal calculations and does not
affect the reported results. To select the representative
domain for a mutation cluster, all domains were ordered
alphanumerically from lowest to highest accession identi-
fier. Preference is given to domains that are listed first
Figure 2 Visual representation of position-based and feature-based domain hotspots. The structure of the Ras-like protein domain
(cd00882) of the human protein Cdc42 (PDB: 1CEE_A) is shown in purple (left). The sequence logo (generated using the WebLogo software
[62]) represents a subset of the Ras-like protein domain from positions 1-152 (right). The functional feature residues corresponding to the GTP/
Mg++ binding site at domain positions 5-11, 54, 110, 111, 113, and 141-143 are highlighted in orange on the structure (left) and are represented
as orange boxes below each domain position in the sequence logo (right). Each of these functional feature protein domain positions will have a
different position-based DS-Score (estimated based on number of mutations at each domain position) but equal feature-based DS-Score
(estimated based on the maximum number of mutations found in any of the binding sites).
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within the list and were defined as root in the domain
hierarchy. If none of the domains in the list is the root
domain of a hierarchy, the representative domain is the
first domain in the list that contain known functional
annotated sites. In addition, when comparing hotspots
using the multi-species DS-Score, the representative
domain model is selected only among those that are
shared among the species.
Assessing the co-occurrence of human diseases and yeast
phenotypes
The significance of overlapping human diseases and yeast
phenotypes was calculated using a right-sided Fisher’s
exact test. The Fisher’s test for each possible pair of
human diseases and yeast phenotypic changes was esti-
mated using the following values: the number of times
the human disease and yeast phenotypic change (H and
Y respectively) overlap, the number of times H overlaps
with a yeast phenotype that is not Y, the number of times
Y overlaps with a human disease that is not H, and the
total number of overlaps between yeast and human.
Human diseases and yeast phenotypes were considered
to overlap if the associated mutations were found to loca-
lize at the same position of an identical domain. To avoid
overestimation due to domain model redundancy, no
protein mutation was counted more than once as over-
lapping with a single human disease or yeast phenotype.
Results
Distribution of mutations in protein domains
To study the distribution of phenotypically relevant muta-
tions at the protein domain level, all proteins from the
considered species, i.e., human and yeast, were aligned to
one or multiple domains and their mutations mapped into
these domains. First, we mapped all phenotypically rele-
vant mutations from yeast and disease mutations from
human to protein domains and analyzed the distribution
of the location of these mutations with respect to their
functional annotation and conservation over species as
measured by the entropy of the domain site. Due to the
redundancy and large hierarchies within the protein
domain database, we observed that the 1,490 yeast and
32,653 human protein mutations were propagated to
11,016 and 323,840 domain mutations respectively (see
Table 1). In Table 1, we also list the total number of
domain sites with mutations and their breakdown into
functionally annotated and conserved domain sites for
yeast and human domains. We found a total of 8,186
domain sites mapped to 11,016 phenotypically relevant
mutations in yeast, 3,992 of them with known function
and 5,950 were conserved domain sites corresponding to
36% and 45% of the total number of yeast domain muta-
tions. Similarly, we reported 323,840 domain mutations in
130,731 domain sites, with 58,096 (18%) corresponding to
mutations in functionally annotated sites and 152,524
(47%) to mutations in conserved domain sites. Using Fish-
er’s exact test, we estimated the enrichment of human and
yeast mutations in functionally annotated and conserved
sites. The results from our analysis produced p-values
close to 0 for functionally annotated conserved sites in
both human and yeast, which indicates a tendency for
both the phenotypically relevant yeast mutations and the
human disease mutations to be located at functional fea-
ture and conserved sites.
Transferring mutational information across species
through protein domains
When comparing the similarity between yeast and human
genomes at the gene and domain levels, we found that the
Homologene database can identify human orthologs for
only 20% of the yeast genes, while 87% of protein domains
found in yeast are also found in human. Most importantly,
we quantified how many of the genetic alterations in the
yeast and human mutation databases could possibly be
related to the other species using either orthologous genes
or common protein domains, as illustrated in Figure 3.
We found that 435 (29%) of the yeast mutations and
10,187 (31%) of the human mutations can only be related
to the other species using common protein domains and
not orthologous genes, i.e., mutations located within a
domain that is common between yeast and human but not
located on orthologous genes. We also identified 610
(41%) yeast and 2,713 (8%) human mutations that could
be related to the other species by means of either the com-
mon domain or orthologous gene. A small number of
mutations, 68 (5%) from yeast and 310 (1%) from human
were related to the other species using orthologous genes
and not common protein domains, for example, a muta-
tion outside of a protein domain region on an orthologous
gene. The remaining mutations, 377 (25%) from yeast and
19,443 (60%) from human, could not be related between
species using either method. This analysis was also per-
formed using the orthologous gene information from
OMA [34] and InParanoid [35] showing only minor varia-
tions in the results.
Yeast and human mutations form hotspots at protein
domain positions
A statistical approach, the DS-Score, was used to identify
clusters of mutations sharing the same domain position.
The method can be used to cluster mutations from one
(Figure 1A) or multiple species (Figure 1B) and clusters
from one species can be associated with mutations from
another species (Figure 1C). Three DS-Score thresholds
were used in this study to identify significantly relevant
clusters of mutations at the domain level, namely 1.6, 1.3,
and 1.0, corresponding to p-values less than or equal to
0.025, 0.05 and 0.10 respectively. The number of domain
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hotspots found at each DS-Score threshold is shown in
Figure 4. Most importantly, in this first analysis of pheno-
typically relevant yeast mutations at the protein domain
level, we found that they cluster at specific domain posi-
tions forming 101, 114, and 135 position-based domain
hotspots at DS-Score thresholds greater than or equal to
1.6, 1.3, and 1.0 respectively. The human mutations also
form domain hotspots at these thresholds, resulting in
719, 884, and 1,085 position-based domain hotspots at
DS-Score thresholds greater than or equal to 1.6, 1.3, or
1.0 respectively.
Using a variation of the DS-Score in which we empha-
size the similarity of domain sites with the same functional
annotation as depicted in Figure 2, we studied the feature-
based domain hotspots in yeast and human. Our results
show that yeast mutations on domains formed 791, 869,
and 1,022 feature-based domain hotspots when using DS-
Score thresholds greater than or equal to 1.6, 1.3, and 1.0
respectively, while human mutations yielded 3,197, 3,446,
and 3,968 feature-based domain hotspots for these
thresholds.
Distribution of phenotypic and disease mutations at
conserved and functional domain sites
The distribution of DS-Score domain hotspots located
on functionally annotated and conserved sites at each
DS-Score threshold is presented in Table 2. Yeast posi-
tion-based domain hotspots were located at highly con-
served sites 55% of the time for the 1.6 threshold, 56% for
the 1.3 threshold, and 50% for the 1.0 threshold. Addition-
ally, the position-based domain hotspots for human were
found at conserved sites 41%, 39%, and 40% of the time
for thresholds 1.6, 1.3, and 1.0 respectively. Despite the
enrichment of domain hotspots at conserved domain sites,
the correlation between entropy and DS-Score is extre-
mely low with Pearson correlation coefficients of -0.04
and -0.16 for human and yeast data, respectively (see Fig-
ures 5A and 5B). To assess the relationship between the
number of domain hotspots per domain with respect to
the sequence conservation of the domain model, we
plotted the average position domain entropy versus their
number of hotspots (see Figures 5C and 5D for yeast and
human respectively). We found a correlation coefficient of
-0.04 for both yeast and human, indicating that almost no
correlation exist between the domain divergency and the
number of domain hotspots it contains. We also analyzed
how frequently the domain hotspots occurred at func-
tional features sites. Our results show that 31%, 31%, and
33% of the position-based domain hotspots are located
within annotated functional feature sites for phenotypically
altering yeast mutations and 17%, 16%, and 16% for
human disease mutations when using 1.6, 1.3, and 1.0
Table 1 Distribution of yeast and human mutations at functional and conserved sites
Yeast Human
Total phenotypically relevant protein mutations 1,490 32,653
Total phenotypically relevant protein mutations inside of domain regions 1,129 (76%) 24,301 (74%)
Total phenotypically relevant domain mutations 11,016 323,840
Domain positions with at least one mutation 8,186 130,731
Domain mutations at functional feature domain sites 3,992 (36%, p-value: ≈ 0) 58,096 (18%, p-value: ≈ 0)
Domain mutations at conserved domain sites 5,950 (45%, p-value: ≈ 0) 152,524 (47%,p-value: ≈ 0)
Counts for yeast and human mutations at functional feature and conserved sites. Fisher’s exact test was used to compute the p-values for significant overlap of
mutations with the functional and conserved sites.
Figure 3 Comparing orthologous genes and common protein domains between yeast and human. Yeast and human protein mutations
that can be related to mutations in other organisms through either orthologous genes from Homologene or through common protein
domains. For both yeast (A) and human (B) mutations, each portion of the graph represents the mutations that could not be related to the
other organism (orange), the mutations that could be related only through Homologene (yellow), the mutations that could be related using
only common protein domains (blue), and the mutations that could be related using either method (purple).
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respectively as thresholds to define the domain position-
based domain hotspots. When analyzing feature-based
domain hotspots at these positions, our results indicated
that 67%, 67%, and 63% of feature-based domain hotspots
in yeast were localized at conserved sites using the 1.6, 1.3,
and 1.0 thresholds respectively and 58%, 57%, and 57% for
human feature-based domain hotspots respectively. Simi-
larly, we found that 91% of the yeast feature-based domain
hotspots, estimated using 1.6, 1.3 or 1.0 DS-Score thresh-
olds, are located in functionally annotated sites. Likewise,
for the human feature-based domain hotspots, we found
that 81%, 78%, and 77% (as defined by the 1.6, 1.3, and 1.0
thresholds respectively) were localized within a function-
ally annotated domain site.
Phenotypically relevant mutations tend to cluster at
domain positions in yeast and human
Results from Table 3 on the analysis of domain hotspots
for both species show that 103, 118, and 177 feature-based
domain hotspots at the 1.6, 1.3, and 1.0 thresholds respec-
tively and one position-based hotspot are common
between yeast and human. The remaining yeast and
human feature-based and position-based domain hotspots
were unique to the organism in which they were found.
One of the advantages of using additional species in the
domain analysis of mutations is its potential for the identi-
fication of new domain sites of phenotypic relevance that
become statistically significant when more annotated
mutations are introduced. Thus, in addition to considering
Figure 4 Yeast and human domain hotspots formed at each DS-Score threshold. Yeast and human position-based and feature-based
hotspots formed DS-Score thresholds greater than or equal to 1.6, 1.3, and 1.0.
Table 2 Distribution of yeast and human domain hotspots at functional features and conserved sites
Yeast (1.6) Yeast (1.3) Yeast (1.0) Human (1.6) Human (1.3) Human (1.0)
Position-based domain hotspots at conserved sites 56 (55%) 64 (56%) 68 (50%) 295 (41%) 346 (39%) 431 (40%)
Feature-based domain hotspots at conserved sites 531 (67%) 582 (67%) 646 (63%) 1,859 (58%) 1,978 (57%) 2,265 (57%)
Position-based domain hotspots at functional features 31 (31%) 35 (31%) 44 (33%) 120 (17%) 137 (16%) 169 (16%)
Feature-based domain hotspots at functional features 721 (91%) 790 (91%) 931 (91%) 2,593 (81%) 2,691 (78%) 3,042 (77%)
The portion of human and yeast DS-Score hotspots at functional feature and conserved sites each threshold level, i.e., 1.6, 1.3, and 1.0.
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each organism’s mutation datasets individually, our
method was used to identify statistically significant clusters
of a combined set of yeast and human mutations (as
shown in Figure 1B). Table 4 outlines results for position-
based and feature-based multi-species domain hotspots. In
total, we found 861, 1,078, and 1,331 position-based
multi-species domain hotspots for the 1.6, 1.3, and 1.0
threshold respectively. In addition, we found 4,243, 4,809,
and 5,439 feature-based multi-species domain hotspots for
the respective thresholds. We identified 143, 187, and 238
position-based multi-species domain hotspots, for the 1.6,
1.3, and 1.0 DS-Score thresholds respectively, that had not
previously been identified when using human or yeast
mutations independently. Similarly, we identified 1,243,
1,533, and 1,672 feature-based multi-species domain hot-
spots, for each DS-Score threshold level respectively, that
had not previously been discovered when considering the
human or yeast datasets independently. To illustrate the
increase in the number of domain hotspots available for
inference, Figures 6A and 6B depict the number of posi-
tion-based and feature-based domain hotspots respectively
that can be obtained using only human data, only yeast
data, and by using a combined set of mutations from both
organisms.
Linking domain hotspots with mutations across
organisms
We analyzed the ability of domain hotspots to identify
relevant mutations in other organisms. In particular, we
focused on testing our ability to use yeast hotspots to
identify disease mutations in humans. As depicted in
Figure 1C, domain hotspots in one organism can be
Figure 5 Correlation between position-based DS-Score and Conservation (estimated by Entropy) for mutations in yeast and human.
The relationship between position-based DS-Score (using 1.3 as a threshold) and the conservation of the mutated domain position, as estimated
by Entropy, is depicted for yeast (A) and human (B) domains. Additionally, the average entropy for each domain is compared with the number
of domain hotspots (using 1.3 as a threshold) in yeast (C) or human (D). In this plot, the total number of domain hotspots is compared to the
average Entropy of all positions in the domain model.







Position-based domain hotspots only found in yeast 100 113 134
Position-based domain hotspots only found in human 718 883 1,084
Feature-based domain hotspots only found in yeast 688 751 845
Feature-based domain hotspots only found in human 3,094 3,328 3,791
Position-based domain hotspots shared between yeast and
human
1 1 1
Feature-based domain hotspots shared between yeast and
human
103 118 177
Position-based and feature-based domain hotspots for yeast and human sharing a common domain position at 1.6, 1.3, and 1.0 DS-Score thresholds.
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mapped to mutations in another organism through pro-
tein domains. When comparing domain hotspots in yeast
to test if they could be mapped to any of the currently
known human disease mutations, results in Table 5 show
that 54 (53.5%), 56 (49.1%), and 65 (48.8%) of position-
based domain hotspots in yeast at the 1.6, 1.3, and 1.0
thresholds can be mapped to at least one human mutation.
The Fisher’s exact test p-values for these results were 2e-
26, 6e-25, and 5e-28 for each respective threshold level.
Similarly, for yeast feature-based domain hotspots, we
identified 562 (71.1%, p-value ≈ 0), 592 (68.1%, p-value ≈
0), and 666 (65.2%, p-value ≈ 0) yeast domain hotspots
that map to at least one human mutation. In addition, in
Additional file 1, we list mappings of human domain hot-
spots into yeast mutational sites, also found to be statisti-
cally significant.
Discussion
Our findings highlight the advantages of using protein
domains to transfer information related to genetic
mutations across species. We show that protein domain
models provide a powerful framework for aggregating
known phenotypically relevant mutation data across large
evolutionary distances, i.e., from human and yeast. As a
model organism, yeast is highly studied, well annotated,
and easy to manipulate genetically. Thus, it is advanta-
geous to transfer known information from genetic disrup-
tions in yeast for analyzing human mutations. To infer
relationships between mutations in different organisms,
most studies use orthologous genes as reference to analyze
mutations [36]. However, our analysis shows that yeast
and human data share more common protein domains
than they do orthologous genes. As a result, we show that
mutations in both the yeast and human databases are bet-
ter mapped across organisms when using shared protein
domains than when using orthologous genes. For instance,
we found that of the 40% of the human mutations that
can be related to yeast, only 9% are through gene orthol-
ogy while 39% can be related using a protein domain fra-
mework with an overlap of 5% of mutations that can be







Total multi-species position-based domain hotspots 861 1,078 1,331
Total multi-species feature-based domain hotspots 4,243 4,809 5,439
Multi-species position-based domain hotspots not identified in
yeast or human
143 187 238
Multi-species feature-based domain hotspots not identified in
yeast or human
1,243 1,533 1,672
Position-based and feature-based domain hotspots identified by applying the DS-Score to a combined set of yeast and human mutations. This table shows the
number of multi-species domain hotspots we can identify at each threshold, as well as the number of domain hotspots that were not previously identified when
analyzing mutations from only yeast or only human.
Figure 6 Increase of domain hotspots by incorporating yeast mutational data. The number of position-based (A) and feature-based
(B) domain hotspots at the 1.6, 1.3, and 1.0 threshold. This figure visually represents the number of domain hotspots formed from human
mutations (blue), the number of domain hotspots from yeast mutations (orange), and the number of new multi-species domain hotspots that
did not reach significance in either the yeast or human analyses individually (purple).
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related by either domain or gene comparisons. This sug-
gests that transferring mutational information by common
protein domains not only vastly increases the number of
mutations that can be transferred but also loses very few
mutations that would have otherwise been transferred
using only gene orthologs. The latter corresponds to, for
instance, human disease mutations in genes for which
there is a yeast ortholog but located outside a protein
domain (only 1% of the human disease mutations in our
analysis). Additionally, the domain approach allows the
aggregation of mutations from multiple genes in each
organism and the identification of relations between muta-
tions located in non-orthologous genes by their functional
annotation, which would normally be missed when analyz-
ing the problem using a gene-centric approach.
Our study of phenotypically relevant mutations using a
protein domain framework confirms that both yeast and
human mutations show a significant tendency to fall within
conserved and annotated functional protein domain sites.
This is in agreement with the conclusions by Miller et al.
[36]. In their study, the authors analyzed human disease
mutations on seven disease-associated genes, cystic fibrosis
transmembrane conductance regulator (CFTR), glucose-6-
phosphate dehydrogenase (G6PD), neural cell adhesion
molecule L1 (L1CAM), phenylalanine hydroxylase (PAH),
paired box 6 (PAX6), the X-linked retinoschisis gene, and a
gene associated with tuberous sclerosis (TSC2). From the
study of mutations in these seven genes and their conserva-
tion across 20 organisms, including human, the authors
concluded that these mutations are in highly conserved
protein positions. Here, we reach similar conclusions, but
we estimated conservation based on the protein domain
models and not at the gene level. Additionally, our findings
at the domain level are consistent with Mooney et al. [27].
The authors conducted a study on a set of 231 human
genes with known disease mutations, showing that human
disease mutations are statistically more likely to be localized
within conserved or functionally relevant positions. To
summarize, our domain-centric analysis confirms findings
from gene-centric studies about enrichment of human dis-
ease mutations with respect to conserved and functionally
annotated sites while identifying the same characteristics
for phenotypically relevant mutations in yeast.
To analyze and compare yeast and human mutations we
used the DS-Score method [18] and identified domain
hotspots of human and yeast phenotypically relevant
mutations. The DS-Score method was previously devel-
oped by our team to study human disease mutations and
modified in this work to include mutations from both spe-
cies resulting in the identification of multi-species domain
hotspots. We also adapted the method for a multi-species
analysis by removing redundant domain hotspots. As an
extreme example of the effect of domain redundancy, a
single cluster of mutations in the yeast IRE1 gene was pro-
pagated to over a hundred domains within the catalytic
protein kinase domain family (cl09925 from the CDD
database [21]), resulting in 120 domain hotspots having
originated from the same cluster of domains. Similarly,
domains from multiple sources (such as an identical
domain from CDD and Pfam databases) could yield
redundant domain hotspots counts. These redundant
domain hotspots are correctly estimated and are of great
relevance for the analysis of mutations in the context of
individual domains. However, when comparing two spe-
cies using redundant domain hotspots, if the cluster of
mutations in the kinase family happens to be common to
both species, we would reach the conclusion that there
were 120 additional hotspots in common between yeast
and human. To avoid overestimation of clusters of muta-
tions that are aggregated at domain level, we defined
domain hotspots as those having originated from a unique
cluster of mutations and applied this method to the com-
parison of position-based and feature-based domain hot-
spots in both species. Using the catalytic protein kinase
domain family as an example, each of the 120 domains in
which the hotspot was found will retain this information,
but only one representative hotspot, cd00180, which is at
the top of the hierarchy in that kinase family from CDD
[21], was considered for the final domain hotspot count
for each species.
In this first-of-a-kind study of yeast mutations at the
domain level, we demonstrate that phenotypically relevant







Position-based domain hotspots in yeast 101 114 135
Feature-based domain hotspots in yeast 791 869 1,022
Position-based domain hotspots in yeast that hit at least one
human mutation
54 (53.5%, p-value: 2e-26) 56 (49.1%, p-value: 6e-25) 65 (48.8%, p-value: 5e-28)
Feature-based domain hotspots in yeast that hit at least one
human mutation
562 (71.1%, p-value ≈ 0) 592 (68.1%, p-value ≈ 0) 666 (65.2%, p-value ≈ 0)
Position-based and feature-based hotspots from yeast that could be associated with a human mutation through a common protein domain position were
quantified (P-values from Fisher exact test are shown).
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mutations in yeast cluster at the domain level just as
human disease mutations do, forming yeast and human
domain hotspots that are the focus of this study. The hot-
spots in yeast present the same patterns as human domain
hotspots in terms of enrichment at protein domain sites
that are conserved and also in sites with known functional
annotation. Neither the yeast nor human DS-Scores were
found to correlate with conservation (as measured by
entropy of the domain site), making the DS-Score method
a complement to other methods for prioritization of muta-
tions with putative phenotypic relevance such as SIFT
[37], that use conservation as principal feature for their
predictions.
We compared the newly found position-based and fea-
ture-based domain hotspots in yeast against those arising
from human mutations. Given the limited number of
mutations with known phenotypic association for each
species, we expect the overlap between hotspots in both
species to be low or non-existent. Indeed, the only posi-
tion-based domain hotspot shared between yeast and
human is at position 246 on PKc (cd00180), a kinase
domain. Surprisingly, the number of hotspots in yeast
and human sharing a common domain and functional
annotation is 108, 114 and 177 when estimated using fea-
ture-based DS-score greater or equal to 1.6, 1.3, and 1.0
respectively. From this analysis, we concluded that the
lower threshold provides a significant increase in the
number of common feature-based domain hotspots
found at the cost of including hotspots with lower signifi-
cance. On the other hand, the similarity of mutation clus-
ters between species increases when using feature-based
DS-Score, a method designed to exploit the manually
curated functional annotation provided by CDD [21].
The feature-based method provides some flexibility when
comparing across species since it includes hotspots
located in different positions for each species, as long as
they are positioned in domain sites from the same
domain and with identical functional annotation. For
instance, using a feature-based threshold of 1.3, we were
able to identify an additional 1,533 feature-based domain
hotspots when considering DS-Scores generated from the
combination of yeast and human mutations. To further
underline the similarities between mutation patterns in
both species, we analyzed the functional annotation of
the domain hotspots and identified several that were
unique to the species in which they were found but were
localized on domain sites with identical annotation to
sites that formed domain hotspots in the other species.
Outlined in Table 6, a threshold greater than or equal to
1.3 was used to highlight examples of functional features
that contained domain hotspots in both species. Domain
positions annotated with the “Active site” functional fea-
ture were found to be identified as position-based
domain hotspots in yeast 28 times and in human 32
times. Other functional features contained domain hot-
spots in both organisms as well. Among others, the
“GTP/Mg2+ binding site” functional feature formed
three yeast domain hotspots and seven human domain
hotspots, and the “Substrate binding site,” contained five
yeast and 17 human domain hotspots.
An example of a domain with several domain hotspots
in human and yeast that highlights the advantages of
using feature-based domain hotspots is the Ras-like
GTPase domain (cd00882 from the CDD [21] database).
While no position-based domain hotspots in the Ras-like
GTPase domain from yeast and human are located at the
same domain position, two hotspots are located at
domain sites with the same functional annotation. The
GTP/Mg++ binding site (highlighted in orange in the
structure of the domain shown in Figure 2) contains
position-based domain hotspots at position ten for the
yeast mutations and at position five for the human muta-
tions. The yeast hotspot in position ten is an example of
mutations related at the domain level, originating from
several genes, ARF2, SEC4, GTR1, and NOG1 that may
not have been identified without analyzing mutations at
the domain level due to the low sequence similarity of
NOG1 (i.e. when using BLAST with E-Value < = 10−3).
The yeast mutations in position ten of cd00882 in genes
ARF2, SEC4, GTR1, and NOG1 were associated with
Table 6 Selected functional feature sites containing domain hotspots in yeast and human
Functional Feature Name Position-based Domain Hotspots in Yeast Position-based Domain Hotspots inHuman
ABC transporter signature motif 1 2
Activation loop (A-loop) 4 99
Active site 28 32
ATP binding site 19 13
Ca2+ binding site 1 2
GTP/Mg2+ binding site 3 7
G1 box 3 6
Substrate binding site 5 17
Functional features found to contain position-based hotspots in human and yeast (using a DS-Score threshold of 1.3 to define the domain hotspots).
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increased sensitivity to cold [38], decreased rates of cyto-
kinesis [39], decreased nutrient uptake [40], and inviabil-
ity due to malformation of the large ribosomal subunit
[41], respectively. In human, this domain position on the
ARL6 gene contains a mutation associated with Bardet-
Biedl syndrome type 3 [42] but not a domain hotspot.
On the other hand, in a different position of the binding
site, position five of the GTP/Mg++ binding region of the
Ras-like GTPase domain contains a human hotspot that
aggregates several positions in human genes that have
been heavily studied due to their prominence in human
diseases. This domain position corresponds to position
12 of both the human HRAS and KRAS genes, from
which many mutations have been implicated in diseases
such as Costello syndrome [43-46] and Congenital myo-
pathy [47,48] and have also been found to be mutated
frequently in somatic tumor samples from patients with
follicular thyroid carcinoma [49], pancreatic carcinoma
[50], and Schimmelpenning-Feuerstein-Mims syndrome
[51], as well as bladder [52], lung [53], and gastric cancers
[54]. While both HRAS and KRAS belong to the same
protein family and are thus often implicated in the same
studies, domain position five also aligns to position 38 of
a gene from a different family, GNAT1, which is not simi-
lar in sequence to HRAS (i.e., HRAS-GNAST1 E-value of
0.53 using BLAST [55]) or KRAS (i.e., KRAS-GNAST1
BLAST E-value of 0.42). The GNAT1 mutation has been
associated with congenital stationary night blindness
[56]. Additionally, other mutations were found in the
GTP/Mg++ binding pocket that were not members of
position-based domain hotspots in either organism that
we were able to identify using our feature-based domain
hotspots. These mutations, sharing common functional
annotation with position-based domain hotspots in both
species, have been associated with autoimmune lympho-
proliferative syndrome [57], somatic pilocytic astrocy-
toma [58], Noonan syndrome [59], and chylomiccron
retention disease [60]. Thus, by extrapolating hotspots in
human and yeast to common functional feature posi-
tions, we were able to identify a common functional dis-
ruption of the GTP/Mg++ binding pocket that causes
different phenotypes when mutated in different genes
sharing the same domain in the same organism as well as
across organisms.
Furthermore, the domain-centric approach across spe-
cies introduced here could also be extended to compare
the particular phenotypes across organisms that can be
related through mutations clustered with this approach,
analogous to the phenotype similarities described by
McGary et al. [12] using gene orthology. In Table 7, we
show a preliminary analysis of this type of phenotype
comparison by highlighting the human disease and yeast
phenotypic annotations that most frequently co-occur
using a domain-centric analysis. A complete list of all
significant co-occurrences of human disease and yeast
phenotypic changes can be found in Additional file 2.
Interestingly, the most significant disease-phenotype
co-occurrence was Wilson’s disease, a human genetic dis-
order in which copper accumulates in tissues, with the
yeast phenotype related to “Gain of function; metal resis-
tance: increased.” This yeast phenotype was derived from
a study that analyzed a mutated copper-transporter gene,
which resulted in a gain of function mutation that enabled
the control of intracellular levels of cadmium through an
enhanced cadmium efflux system [61]. While the relation-
ship between the two phenotypes for the Wilson’s disease
example seems to be clear, for many of the significant
co-occurrence of phenotypes found with our method, the
Table 7 Human diseases and yeast phenotypic changes that co-occur at domain sites
Human Disease Yeast Phenotypic Change Number of
Co-occurrences
Wilson’s disease (WD) (OMIM:277900) Gain of function; metal resistance: increased (PMID: 10743563) 6 (p-value: 2e-14)
Hereditary non-polyposis colorectal cancer type 2
(OMIM:609310)
Mutation frequency: increased (PMID: 16492773) 5 (p-value: 1e-13)
Susceptibility to Breast-Ovarian Cancer, Familial
(OMIM:604370)
Reduction of function; protein/peptide accumulation: increased
(PMID: 10218484)
4 (p-value: 4e-11)
Nemaline myopathy type 3 (OMIM: 161800) Conditional; protein/peptide modification: absent (PMID: 16221887) 4 (p-value: 4e-11)
Familial hyperinsulinemic hypoglycemia type 1
(OMIM: 256450)
Reduction of function; replicative lifespan: decreased (PMID:
21931558)
8 (p-value: 1e-10)
Costello syndrome (OMIM:190020) Inviable (PMID:17443350) 6 (p-value: 1e-09)
Methemoglobinemia, type 1 (OMIM:250800) Reduction of function; heat sensitivity: increased (PMID: 19194512) 4 (p-value: 8e-09)
Crouzon syndrome (OMIM: 123500) Resistance to chemicals: decreased (PMID: 17237519) 6 (p-value: 8e-09)
Kallman syndrome 2 with bimanual synkinesia (OMIM:
136350)
Resistance to chemicals: increased (PMID: 1715094) 4 (p-value: 4e-08)
Friedreich Ataxia (OMIM: 229300) Protein activity: decreased (PMID: 19884169) 3 (p-value: 1e-06)
The top ten yeast phenotypic changes and human diseases that have a significant overlap at the domain level as determined by Fisher’s exact test. Each disease
co-occurrence is counted only once for each uniquely mapping mutation to avoid overestimation due to domain model redundancy.
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relationship between the phenotypes is not apparent. An
in-depth analysis of the molecular mechanisms and exist-
ing literature, as well as experimental validation will be
needed to test and uncover novel hypothesis about mole-
cular similarities between the two species.
Conclusion and future work
This first-of-a-kind study demonstrates the aggregation of
mutations from species spanning large evolutionary dis-
tances such as yeast and human. Using the DS-Score
method as the framework for the integration of molecular
characteristics, such as domain location and functional
annotation of phenotypically relevant mutations, we were
able to identify common mutation patterns from two dis-
tantly related species. The domain-centric approach intro-
duced in this paper provides an ideal framework for the
analysis of mutational data across species since the num-
ber of mutations that can be related from one species to
another is much higher than what could be related
through gene orthology. The feature-based method to
compare mutations across species introduced here repre-
sents a unique way to integrate functional annotation of
domains into the statistical analysis of mutations, shown
here to be extremely advantageous for capturing similari-
ties between mutations across distantly related species.
This analysis also suggests that the approach is useful in
relating phenotypes from yeast and human resulting from
a particular pattern of mutations, such as being localized
at the same domain position or functional site. We plan to
perform a detailed analysis of the molecular basis of these
related phenotypes. Hypotheses derived from this analysis
have great potential for discovering new relationships
between pathways and networks in both species. In addi-
tion, we plan to extend this study to other species to iden-
tify patterns across more closely related species including
mouse, and to increase the number of known phenotypi-
cally relevant domain hotspots by including all mutational
data available for a wide range of organisms.
Additional material
Additional file 1: This file contains information related to the
mapping of hotspots in human to mutations in yeast. This file is in
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Additional file 2: This file contains the human disease and yeast
phenotypic changes the co-occur at domain sites. This file is in
Microsoft Excel format, and can be viewed using Microsoft Excel or
similar applications.
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